A new partnership between MPI Research of Mattawan and two other companies is bringing about a molecular imaging service designed to accelerate drug discovery and development.
, inviCRO and 3D Imaging have worked together on more than 100 imaging projects. From that collaboration, the three companies decided to work together to create a "world-class molecular imaging, radiochemistry, and informatics," service as they describe it.
Work on imaging center, to be located in Mattawan, is expect to begin with a ground breaking soon. The new building will be open by the second quarter of 2014. Services will be available by July 2013, however.
Reduced development costs, better candidate selection and accelerated regulatory approval as expected to be possible as a result of the new imaging service for contract research clients. The new molecular imaging center, located at MPI Research, will provide drug developers with access to the first commercially available cyclotron facility immediately next to animal research facilities housing species ranging from mice to nonhuman primates.
contribution to the partnership is custom tracer applications used in a wide range of animal models, including nonhuman primates, plus state-of-the-art image analysis.
"We believe that the scope and quality of image data generated through this alliance will vastly accelerate drug discovery and development programs," says Jack Hoppin, PhD, Co-founder and Managing Partner of inviCRO
“We have joined the best minds in imaging to form this partnership and I look forward to showing sponsors how we can assist them with their drug and device development programs by offering the best imaging solutions in the world," says MPI Research Chairman, President, and CEO William U. Parfet.
MPI Research is the world's largest single-site preclinical and early clinical contract research organization.
Writer: Kathy Jennings, Second Wave Media
Source: MPI Research